How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about amivantamab

Marketing authorisation indication

2.1

Amivantamab (Rybrevant, Johnson & Johnson) in combination with carboplatin and pemetrexed is indicated for 'the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor (EGFR) Exon 20 insertion mutations'.

Price

2.3

The list price for amivantamab is £1,079 per 350-mg vial (excluding VAT; BNF online, accessed February 2025).

2.4

The company has a commercial arrangement, which would have applied if amivantamab had been recommended.

Comments panel open